3月14日,李嘉诚旗下的和黄医药发布公告称,将在3月31日召开股东特别大会,商议有关出售上海和黄药业45%股权等事宜。而早在今年1月1日,该公司已经提前披露,上海医药将成为接盘者。 上海医药接盘控股 值得注意的是,上海和黄药业是李嘉诚家族持有了24年的优质资产,出售这块重要业务,主要是将资金转向创新药开发。 根据公告,和黄医药拟向金浦健服股权投资管理及上海医药集团分别转让上海和黄药业有限公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.